NRx Pharmaceuticals Rated a “Buy” by EF Hutton amid Surge in Institutional Interest
On October 21, 2024, EF Hutton began covering NRx Pharmaceuticals (MUN:B1Q), giving it a strong Buy recommendation. This marks an optimistic outlook for the company.
Growing Institutional Interest
According to Fintel, there are now 28 funds or institutions with stakes in NRx Pharmaceuticals, a notable increase of 27 funds, or 2,700.00%, just within the last quarter. The average portfolio weight devoted to B1Q has risen to 0.16%, reflecting a staggering increase of 625,839.14%. Over the past three months, institutional ownership surged, with total shares owned rising to 667,000—a dramatic increase of 15,158.66%.
Several major funds hold notable shares in NRx Pharmaceuticals:
- VTSMX – Vanguard Total Stock Market Index Fund Investor Shares: 193,000 shares, 1.80% ownership.
- PSIL – AdvisorShares Psychedelics ETF: 108,000 shares, 1.01% ownership.
- AdvisorShares Investments: 108,000 shares, 1.01% ownership.
- Geode Capital Management: 66,000 shares, 0.61% ownership.
- VEXMX – Vanguard Extended Market Index Fund Investor Shares: 47,000 shares, 0.44% ownership.
Fintel serves as a valuable resource for individual investors, traders, financial advisors, and smaller hedge funds, providing extensive investment research.
The platform offers a wide range of data including fundamentals, analyst reports, ownership statistics, fund sentiment, insider trading, and advanced stock picks, all powered by sophisticated quantitative models.
This information originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
